Extends Labcorp's leadership in genetic testing solutions for oncology and select rare diseases BURLINGTON, N.C. , Aug. 5, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the completion of its acquisition of select assets of Invitae (OTC:NVTAQ), a leading medical genetics company.

Labcorp Holdings Inc LH reported better-than-expected second-quarter financial results and raised its FY24 revenue guidance above estimates on Thursday.

PGDx elio™ plasma focus Dx is the industry's first and only kitted, pan-solid tumor liquid biopsy test that enables tumor mutation profiling – all from a simple blood draw BURLINGTON, N.C., Aug. 2, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it has received De Novo marketing authorization from the U.S. Food and Drug Administration (FDA) for PGDx elio™ plasma focus Dx – the industry's first and only kitted, pan-solid tumor liquid biopsy test.

Labcorp (LH) beats on earnings and revenues in the second quarter, entering the second half of 2024 with robust momentum.

Thursday, Laboratory Corp A reported second-quarter 2024 adjusted EPS of $3.94, up from $3.42 a year ago, beating the consensus of $3.78.

Labcorp (LH) beats on earnings and revenues in the second quarter, entering the second half of 2024 with robust momentum.

The headline numbers for Labcorp (LH) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Labcorp (LH) came out with quarterly earnings of $3.94 per share, beating the Zacks Consensus Estimate of $3.78 per share. This compares to earnings of $3.42 per share a year ago.

Labcorp beat Wall Street expectations for second-quarter profit and revenue on Thursday on strong demand for its diagnostic tests, and raised its sales growth forecast for the year.

Updates Full-Year Guidance Results from Continuing Operations for second quarter 2024 versus last year: Revenue: $3.22 billion versus $3.03 billion Diluted EPS: $2.43 versus $1.74 Adjusted EPS: $3.94 versus $3.42 Free Cash Flow: $432.9 million versus $58.2 million Updated Full-Year 2024 Guidance: Revenue range of 6.4% to 7.5%, includes Invitae impact of ~1.0% Adjusted EPS range of $14.30 to $14.90, includes Invitae dilution of ~$0.40 Free Cash Flow of $0.85 billion to $1.00 billion, includes Invitae cash usage of ~$150 million Share repurchase authorization increased by $1.0 billion to $1.4 billion Launched important new tests in specialty testing areas Introduced Labcorp Global Trial Connect, a suite of central laboratory solutions aimed to accelerate clinical trials BURLINGTON, N.C. , Aug. 1, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the second quarter ended June 30, 2024 and updated full-year guidance.

Here is a sneak peek into how four MedTech companies, LH, BIO, TFX and BRKR, are expected to fare in their second-quarter results, slated to be released tomorrow.

BURLINGTON, N.C., and FREMONT, Calif.